患者对转移性前列腺癌治疗的偏好:一个离散选择实验
Yeuk-Lam Hong1, Chi-Fai Ng1, Kenneth Chun-Wai Wong2
1SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
Clinical genitourinary cancer
|November 23, 2024
概括
转移性前列腺癌患者优先考虑避免不良影响并保持自我护理能力. 治疗成本是一个重要的障碍,特别是在抵抗割的前列腺癌患者中.
科学领域:
- 在瘤学瘤学.
- 医学经济学 医学经济学
- 患者报告的结果
背景情况:
- 调查患者对转移性前列腺癌 (mPC) 治疗属性的偏好.
- 包括激素敏感 (mHSPC) 和抗割 (mCRPC) 疾病状态.
- 了解风险/收益权衡对于治疗决策至关重要.
研究的目的:
- 在mPC治疗中确定风险/益处属性的偏好权重.
- 将不同疾病状态和财务能力的患者优先级进行比较.
- 为共享决策和医疗保健政策提供信息.
主要方法:
- 使用离散选择实验的非干预横截面调查.
- 招募了300名mPC患者 (200个mHSPC,100个mCRPC).
- 混合逻辑模型估计了属性级偏好权重和权衡点.
主要成果:
- 患者强烈支持自我护理能力和预期寿命延长.
- 副作用和治疗成本是显著的威因素.
- mCRPC患者对成本,寿命延长和不良反应的敏感性更高.
结论:
- 在mPC治疗决策中,副作用是关键因素.
- 患者的自我护理能力是患者的一个关键考虑因素.
- 治疗成本仍然是获得治疗的主要障碍.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


